Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China
ITH-testing directed treatment was likely to be the most cost-effective first-line option compared with toripalimab plus chemotherapy and chemotherapy alone for patients with previously untreated ES-SCLC from the Chinese health-care system perspective.
Authors
- Shuo Kang (ORCID: https://orcid.org/0000-0002-8690-4259)
- Xiaohui Wang (ORCID: https://orcid.org/0000-0002-3415-5612)
- Shan Zhao
- Zhu-Lin Pan
Institutions
- Hebei Medical University (CN)
- Second Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1371/journal.pone.0328730
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00